We are pleased to announce the approval of non-exclusive listing agreements with LifeHealthcare Limited ('LifeHealthcare') and Surgical Innovations Limited ('Surgical Innovations') for the supply of orthopaedic implants and associated products ('Orthopaedic Products').

In summary, this will result in LifeHealthcare and Surgical Innovations ranges of Orthopaedic Products being listed in Part III of Section H of the Pharmaceutical Schedule from 1 April 2020.

DHBs will be able to continue to purchase other suppliers' brands of Orthopaedic Products as the agreements are not for sole supply.

Any changes to the original proposal

This decision was subject to the following consultation letters

LifeHealthcare Limited - 23 January 2020

Surgical Innovations Limited - 4 February 2020

No changes have been made to either agreement as a result of consultation.

Who we think will be most interested

Suppliers and Wholesalers

Detail about this decision

In April 2016 PHARMAC issued a request for proposals ('RFP') for orthopaedic implants and associated products. The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

After evaluating LifeHealthcare's and Surgical Innovation's proposals and consulting on the provisional agreements reached with them, PHARMAC has decided to list LifeHealthcare's and Surgical Innovation's ranges of Orthopaedic Products in Part III of Section H of the Pharmaceutical Schedule from 1 April 2020.

These two agreements are the final agreements that will be entered into in the orthopaedic products category as a result of the RFP.

Our response to what you told us

We appreciate the time people took to respond to this consultation.

All consultation responses received by 13 February 2020 and 25 February 2020, respectively, were considered in their entirety in making the decision to approve each agreement.

Contact:

Tel: 021 863 342

Email: media@pharmac.govt.nz

(C) 2020 Electronic News Publishing, source ENP Newswire